BREAKING: The #FDA has granted accelerated approval to linvoseltamab for treating relapsed/refractory multiple myeloma who have progressed after 4 or more prior lines of therapy. #mmsm | @WinshipAtEmory @MadhavDhodapkar.

A new dose optimization trial for rhenium Re 186 obisbemeda in patients with leptomeningeal metastases has been initiated, aiming to refine treatment regimens for this challenging central nervous system complication.

The SonoClear System, a novel acoustic coupling fluid, received #FDA breakthrough device designation for significantly improving intraoperative ultrasound imaging during neurosurgical procedures, especially for aggressive neurological tumors like gliomas.

🎥 Introducing The OncoloGIST — your quick take on the latest in oncology. Get expert insights & key takeaways from top conferences in minutes. Watch now on YouTube! #Oncology #CancerCare #TheOncoloGIST.

Tara Graff, DO, discusses how frontline #CLL treatment has evolved from choosing between continuous oral therapy vs fixed-duration combination therapy to now including new all-oral fixed-duration regimens. @uihealthcare.

New data from a prespecified subgroup analysis of the phase 2 Actuate-1801 part 3B trial highlight the potential of elraglusib+ gemcitabine/nab-paclitaxel for first-line metastatic pancreatic adenocarcinoma treatment. #mPDAC #pancsm.

BREAKING: The #FDA granted accelerated approval to sunvozertinib for adult patients with locally advanced or metastatic #NSCLC harboring EGFR exon 20 insertion mutations. #lcsm.

WATCH: Arturo Loaiza-Bonilla, MD, MSEd, (@DrBonillaOnc) discusses 5-year data from the phase 3 CheckMate 577 trial, presented at the #ASCO25. #gicsm.

Tara Seery, MD, discussed the findings from the QUILT-88 trial in patients with second-line or greater locally advanced or metastatic pancreatic cancer. #ASCO25.

SGR-1505 has received fast track designation from the #FDA for the treatment of adult patients with Waldenström macroglobulinemia who have progressed after at least 2 prior lines of therapy, including a BTK inhibitor.

Experts discuss the methodology, practical adoption strategies for community oncology practices, & the broader implications of AI's role in shaping future oncology workflows. Read the interview with Christine Vecchio & Eirini Schlosser: | @ClevelandClinic.

Theresa Medina, MD, discusses the C-144-01 study of lifileucel in patients with advanced melanoma. #melsm #ASCO25 | @CUCancerCenter.

An expansion cohort of the phase 1 ARC-20 trial evaluating casdatifan and cabozantinib demonstrated promising clinical activity and manageable toxicity in previously treated patients with metastatic #ccRCC. #ASCO25 | @DrChoueiri @DanaFarber.

The phase 3 FORTITUDE-101 trial met its primary end point, showing a statistically significant and clinically meaningful OS benefit with first-line bemarituzumab + mFOLFOX6 in FGFR2b+ unresectable or metastatic gastric/GEJ cancer. #gicsm.

Fengting Yan, MD, PhD, (@FengtingYan) discussed safety outcomes from the TROPION-Breast01 and supportive care for datopotamab deruxtecan in metastatic breast cancer. #bcsm.

The #FDA has granted breakthrough therapy designation to daraxonrasib for the treatment of patients with previously treated metastatic #PDAC harboring KRAS G12X mutations. #pancsm.

The focus on enhancing therapeutic effects while minimizing systemic adverse events continues to be a strategy among investigators in the #NMIBC space. #blcsm. Learn more:

Experts highlight the rising incidence of anal cancer in men and women, and stress the importance of correcting misconceptions that link HPV-related anal cancer exclusively to sexual practices. @MoffittNews @CCCNevada @UTSWMedCenter.

In this video, @RutgersCancer's Biren Saraiya, MD, provides background on the phase 3 AMPLITUDE study evaluating niraparib + abiraterone acetate in metastatic castration-sensitive prostate cancer. #pcsm.

The FDA’s recent approval of tafasitamab + lenalidomide + rituximab marks a pivotal step forward in treating R/R follicular lymphoma. Here, experts share insights on the clinical implications of the approval. #lymsm | @poh_christina @fredhutch.Access here: